Advancing Vitiligo Treatment: Insights on Current and Emerging Therapies by Dr. Rebecca Vasquez
At the Skin of Color Update 2024, we had the honor to learn from Dr. Rebecca Vasquez, Associate Professor at UT Southwestern Medical Center, regarding the evolving field of vitiligo management. Vitiligo affects between 0.5% to 2% of the global population, with no racial or gender preference, yet it carries a significant psychological burden for affected individuals.1 Dr. Vasquez emphasized that vi …
At the Skin of Color Update 2024, we had the honor to learn from Dr. Rebecca Vasquez, Associate Professor at UT Southwestern Medical Center, regarding the evolving field of vitiligo management. Vitiligo affects between 0.5% to 2% of the global population, with no racial or gender preference, yet it carries a significant psychological burden for affected individuals.1 Dr. Vasquez emphasized that vi … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 
At the 2023 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of vitiligo from the renowned researcher and clinician, Dr. John Harris, Professor and Chair of Dermatology at the University of Massachusetts. When a new patient with vitiligo presents to my clinic, I always pull out my phone to consult Dr. Harris’ treatment protocol – I am sure I … 